Search results for "Coronavirus"


 
Results 91 - 100 of about 177 for "Coronavirus".
Sort by: Relevance | Newest | Oldest

Continuous glucose monitoring gains traction in hospitals

Real-time continuous glucose monitoring is seeing a real-world trial after the FDA stated it would not object to its use during the COVID-19 pandemic
https://immattersacp.org/archives/2021/03/continuous-glucose-monitoring-gains-traction-in-hospitals.htm
1 Mar 2021

CDC updates guidance on COVID-19, studies show vitamins don't improve outcomes

The CDC offered new guidance on immunocompromised patients and pulse oximetry's accuracy, and recent trials showed that vitamin D, zinc, and ascorbic acid didn't help COVID-19 patients but prophylactic anticoagulation did.
https://immattersacp.org/weekly/archives/2021/02/23/1.htm
23 Feb 2021

Progress and limitations on vaccines, strokes and readmissions in COVID-19

A report warned that a few health care workers developed COVID-19 shortly after vaccination, and studies showed that strokes were rare in COVID-19 patients but readmissions could not be predicted easily.
https://immattersacp.org/weekly/archives/2021/02/09/1.htm
9 Feb 2021

Q&A: Dealing with COVID-19 vaccine allocation, distribution

The new availability of vaccines has highlighted the challenges of allocation and distribution, which were the focus of a recent forum hosted by ACP and Annals of Internal Medicine.
https://immattersacp.org/weekly/archives/2021/02/02/2.htm
2 Feb 2021

COVID-19 outcomes in health care workers and over the long term, vaccine evidence and uptake among the latest research

A study found that health care workers hospitalized with COVID-19 had shorter stays, while a survey showed high uncertainty about vaccination. Johnson & Johnson released efficacy data on a one-shot vaccine, and a study identified long-term decreases in function among COVID-19 survivors.
https://immattersacp.org/weekly/archives/2021/02/02/1.htm
2 Feb 2021

Latest on COVID-19 and bamlanivimab, vaccines, long-term effects

Bamlanivimab reduced viral load in mild to moderate cases when combined with etesevimab, new vaccine recommendations, research, and educational resources were released, and two studies provided longer-term data on patients who had COVID-19.
https://immattersacp.org/weekly/archives/2021/01/26/1.htm
26 Jan 2021

Anaphylaxis appears rare with COVID-19 vaccine, alternative administration strategies considered

The CDC's monitoring system found low rates of anaphylaxis after a first dose of the Pfizer-BioNTech COVID-19 vaccine, peer-reviewed data were published on the Moderna vaccine, and alternate vaccine administration strategies were evaluated.
https://immattersacp.org/weekly/archives/2021/01/12/2.htm
12 Jan 2021

New research looks at COVID-19 quarantine length in asymptomatic contacts, convalescent plasma for mild disease, related health issues

Seven-day quarantine may be sufficient for contacts without symptoms, older adults with mild disease may benefit from convalescent plasma, and cardiovascular deaths increased during the early stage of the pandemic.
https://immattersacp.org/weekly/archives/2021/01/12/3.htm
12 Jan 2021

Treating the lingering effects of COVID-19

An expert offered tips on helping patients who catch the novel coronavirus and then can't shake the symptoms.
https://immattersacp.org/archives/2021/01/treating-the-lingering-effects-of-covid-19.htm
1 Jan 2021

Getting patients to ‘yes' on COVID-19 vaccines

Experts believe practicing physicians are well positioned to take a lead role combating one of the biggest anticipated obstacles to widespread vaccination: vaccine hesitancy.
https://immattersacp.org/archives/2021/01/getting-patients-to-yes-on-covid-19-vaccines.htm
1 Jan 2021

Result Page: Prev   5   6   7   8   9   10   11   12   13   14   Next